Expression of Plasminogen Activator Inhibitor 2 in the Adult and Embryonic Mouse Tissues

Summary

We have studied the expression of plasminogen activator inhibitor 2 (PAI-2) in the adult mouse and during embryonic development using immunohistochemistry and the polymerase-chain reaction. Mouse PAI-2 mRNA was mainly expressed in the skin, bone-marrow, spleen, lung, thymus, and urinary bladder. Immunohistochemical studies suggested that PAI-2 was synthesized in macrophages and epithelial cells such as skin epithelial cells, transitional cells of the urinary bladder, and mesothelial cell of peritoneum and pleura. PAI-2 mRNA and antigen expression was observed only in the skin of 15 day-old mouse embryos. These data suggest that PAI-2 may play a role in protecting the mouse embryo from the protease attack in the amniotic fluid and also in maintaining and/or protecting the structure of various surfaces in the mouse.

• References

• 1 Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266
• 2 Sakata Y, Eguchi Y, Mimuro J, Matsuda M, Sumi Y. Clot lysis induced by monoclonal antibody against a2 plasmin inhibitor. Blood 1989; 74: 2692-2697
• 3 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. In: Progress in Hemostasis and Thrombosis, Vol. 9. Coller BS, ed. WB Saunders, Philadelphia 1989: 87-115
• 4 Kruithof EKO, Vassalli JK, Schleuning W-D, Mattaliano RJ, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 1986; 261: 11207-11213
• 5 Ye RD, Wun T-Z, Evan Sadler J. Mammalian protein secretion without signal peptide removal. J Biol Chem 1988; 263: 4869-4875
• 6 Kawano T, Morimoto K, Uemura Y. Urokinase inhibitor in human placenta. Nature 1968; 217: 253-254
• 7 Wun T-Z, Reich E. An inhibitor of plasminogen activation from human placenta. J Biol Chem 1987; 262: 3646-3653
• 8 Estelles A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989; 74: 1332-1338
• 9 Estelles A, Gilabert M, Keeton M, Eguchi Y, Aznar J, Grancha S, Espana F, Loskutoff DJ, Schleef RR. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 1994; 84: 143-149
• 10 Schwartz BS, Bradshaw JD. Regulation of plasminogen activator inhibitor mRNA levels in lipopolysaccharide-stimulated human monocytes. J Biol Chem 1992; 267: 7089-7094
• 11 Hibino T, Isaki S, Ohkuma MJ, Kon S, Thoresen S, Astedt B. Epidermal plasminogen activator inhibitor (PAI) is immunologically identical to placental type PAI-2. FEBS 1988; 231: 202-206
• 12 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Analytical Biochem 1987; 162: 156-159
• 13 Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A laboratory manual 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 1989
• 14 Hattori M, Sakaki Y. Dideoxy Sequencing method using denatured plasmid templates. Analytical Biochem 1986; 152: 232-238
• 15 Mimuro J, Muramatsu S, Maekawa H, Sakata Y, Kaneko M, Yoshitake S, Okuma M, Matsuda M. Gene analysis of abnormal fibrinogens with a mutation in the y chain. Int J Hematol 1992; 56: 129-134
• 16 Frohman MA, Dush MK, Martin GR. Rapid production of full-length cDNAs from rare transcripts: Amplification using single gene-specific oligonucleotide primer. Proc Natl Acad Sci USA 1988; 85: 8998-9002
• 17 Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horm GT, Mullis KB, Ehlich HA. Primer-detected enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-491
• 18 Rosenberg AH, Lade BN, Chui D-S, Dunn JJ, Studier FW. Vectors for selective expression of cloned DNAs by T7 RNA polymerase. Gene 1987; 56: 125-135
• 19 Mimuro J, Koike Y, Sumi Y, Aoki N. Monoclonal antibodies to discrete regions in a2 plasmin inhibitor. Blood 1987; 69: 446-453
• 20 Belin D, Wohlwend A, Schleuning WD, Kruithof EKO, Vassalli J-D. Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2. EMBO J 1989; 8: 3287-3294
• 21 Ye RD, Aherm SM, Le Beau MM, Lebo RV, Sadler JE. Structure of the gene for human plasminogen activator inhibitor-2. J Biol Chem 1989; 264: 5495-5502
• 22 Belin D. Biology and facultative secretion of plasminogen activator inhibitor-2. Thromb Haemost 1993; 70: 144-147
• 23 Roberts R. The mouse. Burgress Publishing Co., Minneapolis 1968
• 24 Sappino A-P, Huarte J, Vassalli J-D, Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 1991; 87: 962-970
• 25 Hashimoto K, Wun T-Z, Baird J, Lazarus GS, Jensen PJ. Characterization of keratinocyte plasminogen activator inhibitors and demonstration of the prevention pemphigus IgG-induced acantholysis by a purified plasminogen activator inhibitor. J Invest Dermatol 1989; 92: 310-315
• 26 Rpmer J, Lund LR, Eriksen J, Pyke C, Kristensen P, Dano K. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelization of mouse skin wounds. J Invest Dermatol 1994; 102: 519-522
• 27 Hamilton JA, Whitty GA, Last K, Royston K, Hart PH, Burgress DR. Interleukin-4 suppresses plasminogen activator inhibitor-2 formation in stimulated human monocytes. Blood 1992; 80: 121-125
• 28 Woods DE, Straus DC, Johanson WG, Bass JA. Role of salivary protease activity in adherence of gram-negative bacilli to mammalian buccal epithelial cells in vivo. J Clin Invest 1981; 68: 1435-1440
• 29 Woods DE, Bass JA, Johanson WG, Straus DC. Role of adherence in the pathogenesis of pseudomonas aeruginosa lung infection in cyctic fibrosis patients. Infect Immunol 1980; 30: 694-699
• 30 Sawdey M, Loskutoff DJ. Regulation of murine plasminogen activator inhibitor 1 gene expression in vivo. Tissue specificity and induction by lipo-polysaccharide, tumor necrosis factor-a, and transforming growth factor-p. J Clin Invest 1991; 88: 1346-1353
• 31 Pujade-Lauraine E, Lu H, Mirshahi S, Soria J, Soria C, Kruithof EKO, Lijnen HR, Burtin P. The plasminogen-activation system in ovarian tumors. IntJ Cancer 1993; 55: 27-31
• 32 Gris JC, Schved JF, Marty-Double C, Mauboussin JM, Balmes P. Immuno-histochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. Chest 1993; 104: 8-13
• 33 Gleeson NC, Gonsalves R, Bonnar J. Plasminogen activator inhibitors in endometrial adenocarcinoma. Cancer 1993; 72: 1670-1672
• 34 Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WLJ, Look MP, Klijn JGM, Kramer MD. Plasminogen activator inhibitor-Prognostic relevance in 1012 patients with primary brest cancer. Cancer Res 1995; 55: 1423-1427
• 35 de Vries TJ, Quax PHA, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, van Muijen GNP. Plasminogen activators, their inhibitors and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994; 144: 70-81
• 36 Prendergast GC, Diamond LE, Dahl D, Cole MD. The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol Cell Biol 1990; 10: 1265-1269
• 37 Scherrer A, Kruithof EKO, Grobe JP. Plasminogen activator inhibitor-2 in patients with monocytic leukemia. Leukemia 1991; 5: 479-486
• 38 Kruithof EKO, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and 2 in various disease states. Thromb Haemost 1988; 59: 7-12
• 39 Tran-Thang C, Fasel-Felley J, Pralong G, Hofstetter J-R, Bachmann F, Kruithof EKO. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies by chronic alcoholism or infectious hepatitis. Thromb Haemost 1989; 62: 651-653
• 40 Ozyilkan E, Simsek H, Ozdemir O, Sivri B, Kirazli S, Telatar H. Plasminogen activator inhibitor-2 and alpha-fetoprotein in various liver disease sates. Thromb Haemost 1992; 68: 374
• 41 Schleuning W-D, Medcalf RL, Hession C, Rothenbiihler R, Shaw A, Kruithof EKO. Plasminogen activator inhibitor-Regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells. Mol Cell Biol 1987; 7: 4564-4567
• 42 Cohen RL, Niclas J, Lee WMF, Wun T-Z, Crowley CW, Levinson AD, Evan Sadler J, Shuman MA. Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. J Biol Chem 1989; 264: 8375-8383
• 43 Kumar S, Baglioni C. Protection from tumor necrosis factor-mediated cy-tolysis by over expression of plasminogen activator inhibitor type-2. J Biol Chem 1991; 266: 20960-20964
• 44 Sutter TR, Guzman K, Dold KM, Greenlee WF. Targets for dioxin: Genes for plasminogen activator inhibitor-2 and interleukin-1(3. Science 1991; 254: 415-418
• 45 Antalis TM, Dickinson JL. Control of plasminogen activator inhibitor type 2 gene expression in the differentiation of monocytic cells. Eur J Biochem 1992; 205: 203-209
• 46 Bergonzelli GE, Kruithof EKO, Medcalf R. Transcriptional antagonism of phorbol ester-mediated induction of plasminogen activator inhibitor types 1 and 2 by cyclic adenosine 3,5-monophosphate. Endocrinol 1992; 131: 1467-1472
• 47 Rivkind AI, Lieberman N, Durst AL. Urokinase does not prevent abdominal adhesion formation in rats. Eur Surg Res 1985; 17: 254-258
• 48 Menzies D, Ellis H. Intra-abdominal adhesion and their prevention by tropical tissue plasminogen activator. J Roy Soc Med 1989; 82: 534-535
• 49 Vipond MN, Whawell SA, Thompson JN, Dudley HAF. Peritoneal fibrinolytic activity and intra abdominal adhesions. Lancet 1990; 335: 1120-1122